Takeda Pharmaceutical Co Ltd (FRA:TKD)
€ 25.61 0.16 (0.63%) Market Cap: 40.44 Bil Enterprise Value: 65.50 Bil PE Ratio: 23.27 PB Ratio: 0.97 GF Score: 82/100

Takeda Pharmaceutical Co Ltd Growth & Emerging Markets Strategic Update Call Transcript

Mar 11, 2021 / 11:30AM GMT
Release Date Price: €30.82 (-0.58%)
Christopher David O;Reilly
Takeda Pharmaceutical Company Limited - Global Head of IR & Global Finance

' -

Hello, everyone, and thank you for joining Takeda's investor call focusing on our growth and emerging markets business unit. My name is Christopher O'Reilly, Global Head of Investor Relations.

Before we start, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of today's presentation.

Turning to Slide 3. I would like to introduce our main speakers today: Ricardo Marek, President of Takeda's Growth and Emerging Markets business unit, and Costa Saroukos, Chief Financial Officer.

Moving next to the agenda on Slide 4. First, Costa will give a brief introduction to today's event. Following that,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot